CliffBio
small molecule

DAKLINZA

DACLATASVIR DIHYDROCHLORIDE

Loss of exclusivityAugust 2027latest FDA-listed patent expiry
CompanyBristol Myers Squibb →See this company's full patent-cliff portfolio

Drug detail

Brand nameDAKLINZA
Active ingredientDACLATASVIR DIHYDROCHLORIDE
StrengthEQ 90MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalApril 2016
Marketing statusDISCN

Listed patents

PatentExpiresType
9421192August 2027substance

More from Bristol Myers Squibb

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.